Standard-dose gentamicin does not increase risk of patent ductus arteriosus
Background: Rates of patent ductus arteriosus (PDA) and infection are high in preterm infants. Preterm infants with infection are more likely to develop symptomatic PDA, a potentially fatal disease. Clinically, gentamicin is widely used for early-onset infection in neonates including preterm infants...
Saved in:
| Main Authors: | Ayana Kishibuchi, Toru Akaike, Susumu Minamisawa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-02-01
|
| Series: | Pediatrics and Neonatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957218307502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patent Ductus Arteriosus in Preterm Infants
by: Jia-Yuh Chen
Published: (2012-10-01) -
ENDOVASCULAR TREATMENT OF THE PATENT DUCTUS ARTERIOSUS
by: A. N. Pakholkov, et al.
Published: (2019-04-01) -
Management of patent ductus arteriosus in premature infants.
by: A. Obolonskyi, et al.
Published: (2019-06-01) -
Keeping the Ductus Arteriosus Patent: Current Strategy and Perspectives
by: Anastasios Chatziantoniou, et al.
Published: (2025-01-01) -
Unveiling Silent Patent Ductus Arteriosus with COVID-19
by: Nurhayat Yakut, et al.
Published: (2025-07-01)